Business Description
Novartis AG
ISIN : CH0012005267
Share Class Description:
CHIX:NOVNz: Registered SharesCompare
Compare
Traded in other countries / regions
NOVN.Switzerland0QLR.UKNVS.USANVS.ArgentinaNOTA.GermanyNVS N.MexicoN1VS34.Brazil IPO Date
1996-12-30Description
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.36 | |||||
| Equity-to-Asset | 0.42 | |||||
| Debt-to-Equity | 0.69 | |||||
| Debt-to-EBITDA | 1.47 | |||||
| Interest Coverage | 12.02 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.14 | |||||
| Beneish M-Score | -2.56 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 4.3 | |||||
| 3-Year EPS without NRI Growth Rate | 4.6 | |||||
| 3-Year FCF Growth Rate | 4.2 | |||||
| 3-Year Book Growth Rate | -3.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 8.83 | |||||
| Future 3-5Y Total Revenue Growth Rate | 1.95 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 76.35 | |||||
| 9-Day RSI | 68.67 | |||||
| 14-Day RSI | 62.32 | |||||
| 6-1 Month Momentum % | 1.33 | |||||
| 12-1 Month Momentum % | -0.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | |||||
| Quick Ratio | 0.71 | |||||
| Cash Ratio | 0.33 | |||||
| Days Inventory | 181.15 | |||||
| Days Sales Outstanding | 58.85 | |||||
| Days Payable | 128.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.68 | |||||
| Dividend Payout Ratio | 0.85 | |||||
| 3-Year Dividend Growth Rate | 3.8 | |||||
| Forward Dividend Yield % | 3.68 | |||||
| 5-Year Yield-on-Cost % | 3.99 | |||||
| 3-Year Average Share Buyback Ratio | 3.2 | |||||
| Shareholder Yield % | 9.22 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.79 | |||||
| Operating Margin % | 21.28 | |||||
| Net Margin % | 30.18 | |||||
| FCF Margin % | 20.41 | |||||
| ROE % | 32.69 | |||||
| ROA % | 14.08 | |||||
| ROIC % | 10.29 | |||||
| ROC (Joel Greenblatt) % | 93.98 | |||||
| ROCE % | 14.58 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 13.98 | |||||
| Forward PE Ratio | 13.72 | |||||
| PE Ratio without NRI | 22.97 | |||||
| Shiller PE Ratio | 17.4 | |||||
| Price-to-Owner-Earnings | 10.47 | |||||
| PS Ratio | 4.21 | |||||
| PB Ratio | 5.21 | |||||
| Price-to-Free-Cash-Flow | 20.65 | |||||
| Price-to-Operating-Cash-Flow | 15.23 | |||||
| EV-to-EBIT | 20.89 | |||||
| EV-to-Forward-EBIT | 14.09 | |||||
| EV-to-EBITDA | 12.05 | |||||
| EV-to-Forward-EBITDA | 11.25 | |||||
| EV-to-Revenue | 4.48 | |||||
| EV-to-Forward-Revenue | 4.36 | |||||
| EV-to-FCF | 22.05 | |||||
| Price-to-Projected-FCF | 1.41 | |||||
| Price-to-Median-PS-Value | 1.1 | |||||
| Earnings Yield (Greenblatt) % | 4.79 | |||||
| FCF Yield % | 4.96 | |||||
| Forward Rate of Return (Yacktman) % | 10.2 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novartis AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 44,379.654 | ||
| EPS (TTM) (CHF) | 6.439 | ||
| Beta | 0 | ||
| Volatility % | 16.36 | ||
| 14-Day RSI | 62.32 | ||
| 14-Day ATR (CHF) | 1.531937 | ||
| 20-Day SMA (CHF) | 86.77675 | ||
| 12-1 Month Momentum % | -0.67 | ||
| 52-Week Range (CHF) | 79.192306 - 94.52 | ||
| Shares Outstanding (Mil) | 2,040.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novartis AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novartis AG Stock Events
| Event | Date | Price(CHF) | ||
|---|---|---|---|---|
| No Event Data | ||||
Novartis AG Frequently Asked Questions
What is Novartis AG(CHIX:NOVNz)'s stock price today?
The current price of CHIX:NOVNz is CHF89.63. The 52 week high of CHIX:NOVNz is CHF94.52 and 52 week low is CHF79.19.
When is next earnings date of Novartis AG(CHIX:NOVNz)?
The next earnings date of Novartis AG(CHIX:NOVNz) is 2024-07-18.
Does Novartis AG(CHIX:NOVNz) pay dividends? If so, how much?
The Dividend Yield %  of Novartis AG(CHIX:NOVNz) is 3.68% (As of Today), Highest Dividend Payout Ratio of Novartis AG(CHIX:NOVNz) was 1.19. The lowest was 0.33. And the median was 0.85. The  Forward Dividend Yield % of Novartis AG(CHIX:NOVNz) is 3.68%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers